Interim report July-September 2022

2022-11-03 | Regulatory

Stockholm, November 3, 2022 – Vicore Pharma Holding AB (publ) publishes the interim report for the third quarter 2022.

Important events during the third quarter

  • In August, Vicore announced late-breaker presentation of interim data with C21 in the IPF trial (AIR) at the 2022 ERS congress.
  • In September, Vicore announced continued stabilization and increase in lung capacity with C21 in the IPF trial (AIR) and a second interim analysis planned for Q4 2022.
  • In September, Vicore announced that the phase 3 trial with C21 in COVID-19 (ATTRACT-3) did not reach the primary and secondary endpoints.  Further clinical development in this indication will be discontinued.
  • In September, Vicore announced that clinically relevant doses of C21 increase bloodflow in humans without affecting systemic blood pressure and with no side effects observed.

Important events after the period

  • In October, Vicore announced that a pilot study with the company's digital therapeutic in IPF (COMPANION) showed nearly 50% reduction in anxiety according to the GAD-7 scale.
  • In October, Vicore announced that C103, a new angiotensin II type 2-receptor agonist (ATRAG), was selected as next drug candidate.

Financial overview for the period

July 1 – September 30, 2022

  • Net sales amounted to 0.0 MSEK (0.0)
  • The operating loss was -69.7 MSEK (-97.8)
  • Loss for the period amounted to -68.5 MSEK (-97.6)
  • Loss per share, before and after dilution, was -0.95 SEK (-1.36)
  • On September 30, 2022, cash, cash equivalents and short-term investments amounted to 169.8 MSEK (371.5 MSEK as of December 31, 2021)

January 1 – September 30, 2022       

  • Net sales amounted to 0.0 MSEK (0.0)
  • The operating loss was -227.7 MSEK (-213.7)
  • Loss for the period amounted to -227.7 MSEK (-216.0)
  • Loss per share, before and after dilution, was -3.17 SEK (-3.13)

Financial summary of the group

Amounts in MSEK 2022
Jul-Sep
2021 Jul-Sep 2022
Jan-Sep
2021
Jan-Sep
2021
Jan-Dec
Net sales 0.0 0.0 0.0 0.0 0,0
Operating loss -69.7 -97.8 -227.7 -213.7 -294.8
Loss for the period -68.5 -97.6 -227.7 -216.0 -296.5
Loss per share, before/after dilution (SEK)1 -0.95 -1.36 -3.17 -3.13 -4.25
Research  and development costs/
operating costs (%)2
85.5 93.5 85.3 92.2 91.9
Equity at the end of the period 160.7 462.6 160.7 462.6 383.3
Cash flow from operating activities -66.7 -68.4 -199.7 -189.9 -265.2
Cash and cash equivalents and short-term
investments at the end of the period
169.8 446.9 169.8 446.9 371.5

1 There is no dilution effect for potential ordinary shares for periods where earnings have been negative.

2 Alternative performance measure (APM). Defined on page 21 in the interim report.

CEO Comments

Vicore is developing C21 for rare lung diseases and has a series of new ATRAGs (angiotensin II type 2 receptor agonists) in development for other indications. The first of these, C106, is now in a phase I trial and the second, C103, has been selected for toxicology studies.

In the third quarter of 2022, Vicore’s progress continued. Our clinical experience and knowledge, generated through studies of C21 in a range of conditions including severe lung diseases, now forms the basis for the development of an entirely new class of drugs, angiotensin II type 2 receptor (AT2R) agonists (ATRAGs).

The AT2R is part of the body’s resolution and repair system, protective in several diseases connected to ageing and cell senescence, including idiopathic pulmonary fibrosis (IPF), chronic kidney disease, heart failure and cognitive disorders. Vicore is developing C21 for rare lung diseases and has a series of new ATRAGs in development for other indications. The first of these, C106, is now in a phase 1 trial and the second, C103, has been selected for toxicology studies.

In IPF, the phase 2 trial with C21 (AIR) is progressing following the promising interim findings we announced in February, showing that lung function increased by a clinically meaningful degree in a high proportion of C21-treated patients. We expect to report a second interim analysis during Q4 and are in discussions with advisers and clinical experts on the design for the next trial after which we expect to provide an update on the development program. We also plan to initiate a phase 2a clinical trial with C21 in pulmonary arterial hypertension (PAH), a rare lung disease with significant unmet medical need, in H1 2023. This is based on the strong interim data in IPF as well as preclinical data showing that C21 reverses vascular remodelling and significantly improves hemodynamics.

In September, we reported on a clinical method for rapid assessment of the ATRAGs. Using C21 administered intra-arterially into the forearm at clinically-relevant levels, we were able to show significant dose-dependent increases in local blood flow. The results indicate that the forearm blood flow technique can provide a simple and robust method in humans for exploring clinically relevant doses of C21 and other ATRAGs. This methodology is likely to be important in accelerating transitions from preclinical to clinical investigations across the entire Vicore portfolio.

C21 remains a key component of Vicore’s ongoing clinical programs in IPF and PAH. Following the discontinuation of the ATTRACT-3 phase 3 trial announced in September, Vicore is no longer pursuing opportunities for C21 in COVID-19. The phase 2 ATTRACT trial earlier showed the ability of C21 to reduce alveolar damage in severe COVID-19 infection in the lower respiratory tract, a type of lung injury that waned as new variants of the virus including Omicron evolved later in the pandemic. ATTRACT-3 nevertheless contributed a great deal to Vicore's ongoing programs. It provided an extensive resource of additional safety data underpinning the company’s broader mission as well as clear insights into the role of C21 and other ATRAGs in stimulating alveolar epithelial cells.

A clinical platform company

The next ATRAG from Vicore’s pipeline, C106, is now in a double-blind, placebo-controlled, randomized, single-center phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses in healthy volunteers. Readout from the trial is expected in H1 2023.

C106 is the first of four advanced drug candidates from our ATRAG program with the potential to underpin our transformation into a clinical platform company with a new class of drugs. All four are small molecules with high affinity for the AT2R and are intended for indications beyond rare lung disease. Vicore has shown that ATRAGs have the capacity to address tissue damage and reverse functional losses in lung and kidney tissue.

The ATRAG pipeline has been strengthened with the selection of C103 as the next candidate to move into toxicology studies. Preclinical studies on C103 demonstrate high affinities for the AT2R over the AT1R, a profile that supports a role in preeclampsia, an indication with limited treatment options today.

Positive early AlmeeTM  data

As part of Vicore’s integrated approach in the care of patients with severe lung disease, the company recently reported positive results with the digital therapy (DTx) for patients with pulmonary fibrosis, AlmeeTM. This came from the pilot phase of the COMPANION study. The pilot phase of COMPANION showed that the DTx was safe, functional, and user-friendly. Importantly, even in the small number of IPF patients involved in the pilot phase, it reduced anxiety symptoms by 49%, a positive indicator that it has the potential to address the psychological impact of living with IPF. The pivotal phase of COMPANION will start in Q4 2022, with topline read-outs scheduled for H2 2023.

Vicore continued to maintain a high profile at scientific congresses, presenting data at several prestigious conferences throughout the third quarter. These included the European Respiratory Society (ERS) Congress, the European Society of Cardiology (ESC) Congress, the 6th IPF Summit and the 21st International Colloquium on Lung and Airway Fibrosis (ICLAF 2022).

Overall, Vicore has maintained positive momentum through the third quarter. This is an ideal moment to extend my gratitude to all involved in Vicore for their support in making our ambition, to unlock the potential of ATRAGs – a new class of drugs, possible.

Carl-Johan Dalsgaard

Interim report July-September, 2022; https://vicorepharma.com/investors/financial-reports/

For further information, please contact:

Carl-Johan Dalsgaard, CEO, tel: +46 70 975 98 63, carl-johan.dalsgaard@vicorepharma.com  

Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com

This information was submitted for publication on November 3, 2022 at 08:00 CET.

Vicorepharma

On vicorepharma.com, we use so-called cookies to analyze how our website is used in order to optimize and improve it. You choose yourself whether you want to consent to our use of cookies.

Vicorepharma is responsible for placing cookies on the website and for the processing of your personal data collected by them. For more information about our processing of your personal data, see our privacy policy

Cookie policy

Your consent applies to the following domain: vicorepharma.com
The cookie policy was last updated: 2023-06-29

Privacy Policy

Show the cookies used on our website

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

 

What are cookies?

A cookie is a small text file that is placed on your device (computer/mobile/tablet that has access to the internet) by the website you visit – if you give your consent to this. The cookie can, for example, recognize you as a user when you visit our website and make it possible to remember important information that makes your visit more comfortable and provides an improved user experience. Cookies are so-called passive files that cannot spread dangerous software or viruses on your mobile device or computer.

There are two types of cookies, permanent cookies and session cookies. At vicorepharma.com we use both permanent cookies and session cookies. Permanent cookies are saved as a file on the computer for a certain time until the server that placed them, or you as a visitor choose to delete them. Session cookies are temporarily stored when you as a visitor are on the website and disappear when you close your browser.

Cookies can also be divided into first-party cookies and third-party cookies. First-party cookies are placed by the website you are visiting, while third-party cookies are placed by another website. At vicorepharma.com, we use both first-party cookies and third-party cookies.

 

How to avoid cookies

When you visit our website, you can refuse all or certain types of cookies. You can also withdraw or change your consent at any time by clicking here.

You can also block cookies by changing the settings in your browser. Then your browser will automatically refuse cookies or inform you when a website requests to store cookies.

After your visit, you can review and delete the permanent cookies that have been stored in your browser. In the list below, you will see the name of the cookies vicorepharma.com saves so that you can easily identify them.

Here you will find more information about how to manage cookies in your browser:

 

Cookies used by third parties

On vicorepharma.com there may be content that is embedded from YouTube. YouTube places cookies in your browser when you visit youtube.com or when you click on embedded content from YouTube on our website. vicorepharma cannot control these cookies or the personal data and information that may be collected. vicorepharma does not use the targeted marketing services offered by YouTube. As a user, you therefore need to check YouTube’s website for further information on how they manage cookies, what information they collect and how you can delete any third-party cookies.

 

Cookies used on vicorepharma.com

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

General

Vicore Pharma Holding AB (“Vicore”) shall only process personal data in accordance with applicable data protection law and high industry standards.

 

Personal data.

Vicore processes personal data provided to us;
(i) by you in the day-to-day communications, or

(ii) in connection with entering into or performing an agreement or business arrangement with you, or
(iii) by a third party allowed by law or your consent.

The personal data may consist of contact and identification details and other information relevant to the situation.

 

Purpose.

Vicore process personal data for the purpose of communicating with you and to perform, manage and comply with agreements between us as well as rights and obligations which are allowed by law or applicable regulation.

 

Legal grounds.

The legal grounds for processing personal data is either;
(i) your consent which shall be considered provided when you either voluntary submit the personal data or enter into an agreement with us, or
(ii) a legitimate interest allowed under law.

 

Security

Vicore shall use adequate technical and organisational security measures to protect the personal data from loss and to safeguard against access from unauthorised persons.

Transfers of personal data may only occur;
(i) to third parties who perform services on Vicore behalf and who may only process personal data in accordance with our instructions, and may not use personal data for their own purposes; and
(ii) outside the EU/EEA only in accordance with applicable data protection laws and subject to the EU Commission’s standard contractual clauses, and
(iii) as otherwise permitted by law or your consent.

Duration.

The duration we process personal data is limited to what is reasonable for the purpose of the processing, unless otherwise required or permitted by law.

 

Rights

Vicore is the controller of the personal data processing, meaning that we are responsible for that the personal data is processed correctly and in accordance with applicable data protection laws.

Unless prevented by applicable law, regulation or agreement data subjects have the right to;
(i) know what personal data we process about them,
(ii) request that we rectify or erase inaccurate or incomplete personal data
(iii) object to specific processing of personal data, and
(iv) receive the personal data provided by them and have the personal data transferred to another party responsible for data processing.

All communications with Vicore regarding how we process personal data or exercise of any of your rights can be sent by e-mail to info@vicorepharma.com or by post to the address above.

Reports and complaints can also be directed to Datainspektionen who is the supervisory authority for our processing of personal data.